CLASSIC — Adjuvant Capecitabine and Oxaliplatin (CAPOX) After D2 Gastrectomy for Gastric Cancer

Phase 3 · 2012 · Gastric Cancer

Design

Randomized 6 months of adjuvant capecitabine plus oxaliplatin vs surgery alone after D2 gastrectomy.

Population

Stage II/IIIB gastric cancer resected with D2 lymphadenectomy.

Primary Endpoint

disease-free survival (DFS)

Key Result

Adjuvant CAPOX improved 3-year DFS (74% vs 59%) and 5-year OS after curative D2 resection.

Guideline Impact

Category 1 adjuvant CAPOX after D2 resection in gastric cancer guidelines